MX2022005345A - Terapia de combinación para el tratamiento de cáncer cerebral. - Google Patents
Terapia de combinación para el tratamiento de cáncer cerebral.Info
- Publication number
- MX2022005345A MX2022005345A MX2022005345A MX2022005345A MX2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A MX 2022005345 A MX2022005345 A MX 2022005345A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- brain cancer
- certain embodiments
- treatment
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001142—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
En la presente se proporcionan moléculas de ácido nucleico, proteínas, composiciones y métodos para tratar cáncer cerebral en un sujeto. En algunas modalidades, las composiciones comprenden antígenos de cáncer hTERT, WT-1 y PSMA. En algunas modalidades, las composiciones también comprenden un adyuvante. Los métodos comprenden administrar a un sujeto que lo necesita los antígenos de cáncer. De acuerdo con determinadas modalidades, los métodos implican además administrar el adyuvante y un anticuerpo anti-PD-1. En determinadas modalidades, los métodos comprenden además administrar radioterapia y/o un agente quimioterapéutico. En determinadas modalidades, los métodos han demostrado ser clínicamente seguros, clínicamente eficaces, o ambos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930417P | 2019-11-04 | 2019-11-04 | |
| US202062988102P | 2020-03-11 | 2020-03-11 | |
| US202063018060P | 2020-04-30 | 2020-04-30 | |
| US202063070987P | 2020-08-27 | 2020-08-27 | |
| PCT/US2020/058891 WO2021092019A1 (en) | 2019-11-04 | 2020-11-04 | Combination therapy to treat brain cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005345A true MX2022005345A (es) | 2022-08-11 |
Family
ID=75686760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005345A MX2022005345A (es) | 2019-11-04 | 2020-11-04 | Terapia de combinación para el tratamiento de cáncer cerebral. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210128710A1 (es) |
| EP (1) | EP4055033A4 (es) |
| JP (1) | JP2023500337A (es) |
| KR (1) | KR20220097928A (es) |
| CN (1) | CN114901677A (es) |
| AU (2) | AU2020380288B2 (es) |
| BR (1) | BR112022008164A2 (es) |
| CA (1) | CA3156227A1 (es) |
| CO (1) | CO2022007361A2 (es) |
| IL (1) | IL292462A (es) |
| MX (1) | MX2022005345A (es) |
| PH (1) | PH12022551078A1 (es) |
| WO (1) | WO2021092019A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| CN113447654B (zh) * | 2021-07-15 | 2022-03-22 | 广州济士源生物技术有限公司 | 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断前列腺癌产品中的应用 |
| AU2022328341A1 (en) * | 2021-08-13 | 2024-04-04 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| WO2014134165A1 (en) * | 2013-02-26 | 2014-09-04 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| KR20190003938A (ko) * | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| JP2019527737A (ja) * | 2016-08-09 | 2019-10-03 | アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ | Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス |
| CN119326876A (zh) * | 2016-09-30 | 2025-01-21 | 宾夕法尼亚大学理事会 | Tert免疫原性组合物及使用其的治疗方法 |
| EA201990624A1 (ru) * | 2017-03-07 | 2019-09-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Иммуногенные композиции tert и способы лечения с их использованием |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CN120796389A (zh) * | 2017-05-26 | 2025-10-17 | 埃皮森特Rx股份有限公司 | 携带转基因的重组腺病毒 |
| CN109486828B (zh) * | 2018-12-27 | 2022-05-31 | 广东暨大基因药物工程研究中心有限公司 | 一种编码重组人白细胞介素12的基因及其应用 |
| CN120939219A (zh) * | 2019-05-13 | 2025-11-14 | 瑞泽恩制药公司 | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 |
| WO2021051065A1 (en) * | 2019-09-12 | 2021-03-18 | Inovio Pharmaceuticals, Inc. | Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same |
| KR20220091576A (ko) * | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
-
2020
- 2020-11-04 US US17/089,244 patent/US20210128710A1/en active Pending
- 2020-11-04 JP JP2022525913A patent/JP2023500337A/ja active Pending
- 2020-11-04 BR BR112022008164A patent/BR112022008164A2/pt unknown
- 2020-11-04 MX MX2022005345A patent/MX2022005345A/es unknown
- 2020-11-04 CA CA3156227A patent/CA3156227A1/en active Pending
- 2020-11-04 AU AU2020380288A patent/AU2020380288B2/en active Active
- 2020-11-04 KR KR1020227018389A patent/KR20220097928A/ko active Pending
- 2020-11-04 EP EP20884253.4A patent/EP4055033A4/en active Pending
- 2020-11-04 PH PH1/2022/551078A patent/PH12022551078A1/en unknown
- 2020-11-04 CN CN202080088086.1A patent/CN114901677A/zh active Pending
- 2020-11-04 WO PCT/US2020/058891 patent/WO2021092019A1/en not_active Ceased
- 2020-11-04 IL IL292462A patent/IL292462A/en unknown
-
2022
- 2022-05-27 CO CONC2022/0007361A patent/CO2022007361A2/es unknown
-
2024
- 2024-04-30 AU AU2024202791A patent/AU2024202791A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022007361A2 (es) | 2022-06-10 |
| EP4055033A4 (en) | 2023-12-06 |
| CN114901677A (zh) | 2022-08-12 |
| AU2020380288A1 (en) | 2022-06-16 |
| US20210128710A1 (en) | 2021-05-06 |
| KR20220097928A (ko) | 2022-07-08 |
| WO2021092019A1 (en) | 2021-05-14 |
| AU2020380288B2 (en) | 2024-02-01 |
| IL292462A (en) | 2022-06-01 |
| BR112022008164A2 (pt) | 2022-07-12 |
| CA3156227A1 (en) | 2021-05-14 |
| JP2023500337A (ja) | 2023-01-05 |
| PH12022551078A1 (en) | 2024-06-19 |
| AU2024202791A1 (en) | 2024-05-23 |
| EP4055033A1 (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007361A2 (es) | Terapia de combinación para el tratamiento de cáncer cerebral | |
| CL2024001607A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112019021822A2 (pt) | Terapia de combinação | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| BR112022021956A2 (pt) | Métodos, terapias e usos para o tratamento de câncer | |
| NI201500002A (es) | Agentes de unión de rspo3 y usos de los mismos. | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112015024621A8 (pt) | usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi | |
| MX2022001249A (es) | Tratamiento de tumores evasivos inmunitarios. | |
| BR112021010634A2 (pt) | Anticorpos antiperiostina e usos dos mesmos | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| CO2021005234A2 (es) | Métodos de tratamiento | |
| CO2021005207A2 (es) | Métodos de tratamiento | |
| ZA202100467B (en) | Combination therapy | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2018012392A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| CL2021001172A1 (es) | Uso de tivozanib para tratar sujetos con cáncer refractario. |